SoftOx Solutions AS — Investor Presentation 2020

Dec 15, 2020

SoftOx Solutions AS A Norwegian MedTech Company listed on Euronext Growth, Presentation Q3 2020

Disclaimer

This Presentation has been produced by SoftOx Solutions AS (the "Company" or "SoftOx"), solely for use at the presentation to investors held in connection with the proposed private placement of shares by the Company. This presentation is strictly confidential and may not be reproduced or redistributed, in whole or in part, to any other person. To the best of the knowledge of the Company and its Board of Directors, the information contained in this Presentation is in all material respect in accordance with the facts as of the date hereof, and contains no material omissions likely to affect its import. However, no representation or warranty (express or implied) is made as to, and no reliance should be placed on, any information, including projections, estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, arising directly or indirectly from the use of this Presentation. This Presentation contains information obtained from third parties. Such information has been accurately reproduced and no facts have been omitted that would render the reproduced information to be inaccurate or misleading, as far as the Company is aware and able to ascertain from the information published by these third parties. This document contains certain forward-looking statements relating to the business, financial performance and results of the Company and/or the industry in which it operates. Forward-looking statements concern future circumstances and results and other statements that are not historical facts, sometimes identified by the words "believes", "expects", "predicts", "intends", "projects", "plans", "estimates", "aims", "foresees", "anticipates", "targets", and similar expressions. The forward-looking statements contained in this Presentation, including assumptions, opinions and views of the Company or cited from third party sources, are solely opinions and forecasts which are subject to risks, uncertainties and other factors that may cause actual events to differ materially from any anticipated development. The Company does not provide any assurance that the assumptions underlying such forward-looking statements are free from errors, nor does the Company accept any responsibility for the future accuracy of the opinions expressed in this Presentation or the actual occurrence of the forecasted developments. The Company does not assume any obligation, except as required by law, to update any forward-looking statements or to conform these forward-looking statements to our actual results. AN INVESTMENT IN THE COMPANY INVOLVES RISK, AND SEVERAL FACTORS COULD CAUSE THE ACTUAL RESULTS, PERFORMANCE OR ACHIEVEMENTS OF THE COMPANY TO BE MATERIALLY DIFFERENT FROM ANY FUTURE RESULTS, PERFORMANCE OR ACHIEVEMENTS THAT MAY BE EXPRESSED OR IMPLIED BY STATEMENTS AND INFORMATION IN THIS PRESENTATION. THESE FACTORS INCLUDE, E.G., RISKS OR UNCERTAINTIES ASSOCIATED WITH THE COMPANY'S BUSINESS, SEGMENTS, DEVELOPMENT, GROWTH MANAGEMENT, FINANCING, MARKET ACCEPTANCE AND RELATIONS WITH CUSTOMERS, AND, MORE GENERALLY, GENERAL ECONOMIC AND BUSINESS CONDITIONS, CHANGES IN DOMESTIC AND FOREIGN LAWS AND REGULATIONS, TAXES, CHANGES IN COMPETITION AND PRICING ENVIRONMENTS, FLUCTUATIONS IN CURRENCY EXCHANGE RATES AND INTEREST RATES, AND OTHER FACTORS. SHOULD ONE OR MORE OF THESE RISKS OR UNCERTAINTIES MATERIALIZE, OR SHOULD UNDERLYING ASSUMPTIONS PROVE INCORRECT, ACTUAL RESULTS MAY VARY MATERIALLY FROM THOSE DESCRIBED IN THIS PRESENTATION. THE COMPANY DOES NOT INTEND, AND DOES NOT ASSUME ANY OBLIGATION, TO UPDATE OR CORRECT THE INFORMATION INCLUDED IN THIS PRESENTATION. No representation or warranty (express or implied) is made as to, and no reliance should be placed on, any information, including projections, estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein arising directly or indirectly from the use of this document. By attending or receiving this Presentation you acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the Company's business. This Presentation is confidential and is being communicated in the United Kingdom to persons who have professional experience, knowledge and expertise in matters relating to investments and are "investment professionals" for the purposes of article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 and only in circumstances where, in accordance with section 86(1) of the Financial and Services Markets Act 2000 ("FSMA") the requirement to provide an approved prospectus in accordance with the requirement under section 85 FSMA does not apply. Consequently, the Investor understands that the Private Placement may be offered only to "qualified investors" for the purposes of sections 86(1) and 86(7) FSMA, or to limited numbers of UK investors, or only where minima are placed on the consideration or denomination of securities that can be made available (all such persons being referred to as "relevant persons"). This presentation is only directed at qualified investors and investment professionals and other persons should not rely on or act upon this presentation or any of its contents. Any investment or investment activity to which this communication relates is only available to and will only be engaged in with investment professionals. This Presentation (or any part of it) is not to be reproduced, distributed, passed on, or the contents otherwise divulged, directly or indirectly, to any other person (excluding an investment professional's advisors) without the prior written consent of the

Company. IN RELATION TO THE UNITED STATES AND U.S. PERSONS, THIS PRESENTATION IS STRICTLY CONFIDENTIAL AND IS BEING FURNISHED SOLELY IN RELIANCE ON APPLICABLE EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED. THE SHARES HAVE NOT AND WILL NOT BE REGISTERED UNDER THE U.S. SECURITIES ACT OR ANY STATE SECURITIES LAWS, AND MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES, OR TO OR FOR THE ACCOUNT OR BENEFIT OF U.S. PERSONS, UNLESS AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES ACT IS AVAILABLE. ACCORDINGLY, ANY OFFER OR SALE OF SHARES WILL ONLY BE OFFERED OR SOLD (I) WITHIN THE UNITED STATES, OR TO OR FOR THE ACCOUNT OR BENEFIT OF U.S. PERSONS, ONLY TO QUALIFIED INSTITUTIONAL BUYERS ("QIBs") IN PRIVATE PLACEMENT TRANSACTIONS NOT INVOLVING A PUBLIC OFFERING AND (II) OUTSIDE THE UNITED STATES IN OFFSHORE TRANSACTIONS IN ACCORDANCE WITH REGULATIONS. ANY PURCHASER OF SHARES IN THE UNITED STATES, OR TO OR FOR THE ACCOUNT OF U.S. PERSONS, WILL BE DEEMED TO HAVE MADE CERTAIN REPRESENTATIONS AND ACKNOWLEDGEMENTS, INCLUDING WITHOUT LIMITATION THAT THE PURCHASER IS A QIB. This Presentation speaks as of December 2020. Neither the delivery of this Presentation nor any further discussions of the Company with any of the recipients shall, under any circumstances, create any implication that there has been no change in the affairs of the Company since such date.

Highlights Q3 2020, including selected information for Q4

	Highlights Q3 2020, including selected information for Q4
Finance	• Year to date pre-tax results ended 30.9.2020 with a loss of NOK 29 million (loss of NOK 15 million). Results are characterised by high levels of activity in research and development in addition to preparatory work ahead of the launch of our disinfectants in new markets
RnD	• Clinical study of the SoftOx Wound Irrigation Solution (SWIS) was approved and has commenced • The Danish Medicines Agency recommended further development of the SoftOx Inhalation Solution (SIS) for the treatment of respiratory infections, including COVID-19
Awards	• The US Department of Defence (DoD) awarded SoftOx app. USD 2 million for the research and development of the SoftOx Biofilm Eradicator (SBE) • SoftOx has been awarded conditional certification of its disinfectants in the EU. The Swedish Chemicals Agency has processed and recommended SoftOx Solutions' disinfectants, including AntiVir, for certification.

Financial highlights

SoftOx Solutions Group
NOK 1,000	Q3 2020	Q3 2019 Change		YTD 2020	YTD 2019 Change		FY 2019
Other operating revenues	1 738	1 309		9 243	3 866		4 099
Total operating revenues	1 738	1 309	33 %	9 243	3 866	139 %	4 099
Personnel expenses	4 269	3 088	38 %	10 929	8 044	36 %	11 197
Other operating expenses	9 114	3 953		26 207	10 169		13 071
Depreciation	579	273		1 480	828		1 701
Depreciation, goodwill
Total operating expenses	13 962	7 314	91 %	38 615	19 041	103 %	25 969
Operating result	-12 224	-6 005		-29 372	-15 175		-21 870
Net result before taxes	-12 199	-6 004	103 %	-29 245	-15 137	93 %	-22 178
Tax							5842
Net result after tax							-16 336

Operating revenue, increase driven by sale of disinfection products and public grants

Operating expenses, increase driven by

• Increased production capacity
• Research and development
• Cost of goods sold

Financial highlights

Cash flow statement	Q3 2020	Q3 2019	YTD 2020	YTD 2019
SoftOx Solutions Group
NOK 1,000
Cash flow from operating activities	-9 932	-1 879	-43 978	-16 109
Net result before taxes	-12 199	-6 004	-29 245	-15 137
Depreciation	579	273	1 480	828
Change in current assets	-879	-598	-7 865	-2 490
Change in current liabilities	2 566	4 450	-8 349	690
Cash flow from investment activities	-213	0	-7 674	0
Investments in non-current assets	-213		-7 674	0
Cash flow from financing activities	85	317	1027	16 172
Proceeds from equity issues	0	0	1 010	17 894
Other financing activities	0	300	-114	-1 700
Translation differences	85	17	131	-22
Net change in cash and cash equivalents	-10 061	-1 562	-50 625	63
Cash and cash equivalents at end of period	25 370	1 300	25 370	1 300

Net change in cash and cash equivalents

• Approx. NOK 11 mill due to repayment of short-term loans
• Approx. NOK 8 mill in increased production facilities

SoftOx at a Glance

Eradicating infections and fighting

• A strong medical technology platform developed over 10+ years • The medical products being developed on this platform will effectively eradicate bacteria and viruses without creating resistance unlike existing antibiotics resistance • A non-alcoholic, exceptionally efficient hand disinfectant • Biofilm Eradicator (SBE) and Wound Irrigation Solution (SWIS) • Inhalation solution for respiratory tract infections (SIS) • Strong development and research support from Bispebjerg Hospital and Copenhagen University • US Navy Medical Research Centre sponsoring the development of the SBE • Blue Cross/Blue Shield recommendation of the SBE product • The largest market opportunities for SoftOx are in the professional health sectors worldwide • All markets targeted by SoftOx are billion \$ opportunities

Strong patented product

Strong international research and market support

Targeting large markets

• portfolio
  -
  -
  -
  -
  -
• Currently in dialogue with leading players in some of the world´s largest markets

Contents

Global Challenges Targeted by SoftOx

Antibiotic resistance

• The ability of bacteria and other microorganisms to resist the effects of an antibiotic to which they were once sensitive » WHO estimates that drug-resistant diseases could cause 10 million deaths each year • Aggregated bacteria often covered by slime (biofilm matrix), which
  • by 2050 [1
  • » The world needs a new antibiotic preventing and removing resistant infections without inducing new resistance

Biofilm resistance

• acts as a fortress and protects bacteria
  • » 1 to 2 percent of the total population are projected to experience a chronic wound during their lifetime in developed countries [2
  • » The world needs a new antibiotic preventing and removing infections protected by a biofilm

Virus

• globally [4 2) Chandan K. Sen, PhD, Wound Repair Regen, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2810192/
  • » The world needs a broad spectrum, first-line alternative to vaccines

1) https://www.who.int/antimicrobial-resistance/interagency-coordination-group/IACG_final_report_EN.pdf?ua=1

8 3)Wu, Katherine J. National Geographic Society. April 2020

demonstrated our competitive advantage by: Securing a unique chemical stability between two of the body's own SoftOx – A Technology Product Platform Eradicating Infections

Over the past 10 years, SoftOx has developed and

• antimicrobial agents
• Generating unique antimicrobial effects against all known groups of microbes
• Tweaking the concentrations between the two antimicrobials to develop a broad range of products, satisfying different medical needs
• Does not induce antimicrobial resistance
• Developing a solution that is non-toxic at effective concentrations
• Creating an easily scalable production method

Unrivalled Effect on Bacteria in Biofilms

New ways of eradicating infections and fighting antimicrobial resistance

Antibiotics are Struggling with Resistant Microbes

Platform products under development • Wound irrigation solutions for acute wounds (SWIS) » Topical infection prevention • Infections remover in chronic wounds (SBE) » Topical infection remover • Inhalation solution (SIS) » Topical infection remover in the respiratory tract • Hand disinfection » Topical infection prevention for non-compromised skin Respiratory virucidal infections* Hand eczema* Venous leg ulcers* Acute surgical wounds* SoftOx is replacing today's antibiotics to become the first line of treatment

* Development projects already started

Contents

• New Ways of Eradicating Infections
• The Product Portfolio
• Wound Care Products
• Respiratory Tract Solutions

• Production and Distribution
• Summary

SoftOx Product Development Methodology*

12 * There are minor differences in the development stages between the products, for details, see each product description later in the presentation

Actual clinical development progress versus estimates Dec-2019

	Actual clinical development progress versus		estimates Dec-2019
Study	Objectives	Cost (NOK)	Expectations December 2019	Status 2020
Animal (minipigs); MAX dose; wound healing	RTC: Local tolerance, systemic effects and pathology in minipigs after repeated dosing (continuously for 28 days) with increasing SOX-strengths. Aiming to achieve maximal tolerable dose.	4m	Q2-3 2020	Completed
Biocide (SafeDes) Skin Tolerability	Clinical testing of SafeDes hand disinfectant on healthy and experimentally induced eczema with respect to skin barrier functions. Comparison with alcohol-based products.	1.5m	Q3-2020	Completed
Clinical Study Medical Device (SWIS-02)	Pivotal, confirmatory, comparative trial in subjects with superficial (blister) and full depth (biopsy) wounds to demonstrate safety and performance, with focus on wound healing. n = est. 40 (tbd).	10m	Late 2020	On schedule
Phase I drug study	To test drug candidates in relevant patient population (infected chronic wounds), dose escalation, safety and efficacy measures. n = est. 30 (tbd). Clinical Study (phase I) under development.	25m	TBD, 2021	Slightly delayed
13 SOX: SoftOx	test solutions

On track	on
		most projects
1
Hand Disinfection	In vitro/EN studies	Preclinical/EN studies	PoC/Pilot	Confirmative studies	Application market approval	Post market studies
SafeDes			N/A	2020		TBD
2 Animals
Infection prevention				1H2020	N/A
Infection treatment			1H2020		N/A	2H2020
Device & Drug
				2020
SWIS 3
4 SBE		1H2020	2020/2021	TBD

Infection prevention		1H2020	N/A
Infection treatment		1H2020	N/A	2H2020

^• Blue arrow represent expectations 2019

14 • Green arrow represent actual 2020

Probability of Success for Developing Medical Drugs Key points in SoftOx development • Topical usage moderate the risk factors • Active substances are well known in the human body • Solid clinical experience for each of the active substances • In vitro studies show clear combination effect

-

-

-

Probabilities by disease

SoftOx is developing products within an area that has one of the highest probabilities of success from Phase I to Approval

15

Collaboration with World-Leading Scientists and Research Organisations

Key research development partners Key support partners

US Department of Defense (DoD) awarded SoftOx \$1.977 million (USD) for research and development of the SoftOx Infection remover (Biofilm Eradicator). NMRC and SoftOx have weekly meetings, monthly reporting, and are active partners in the clinical development

and a major contributor to the SoftOx advisory board.

SoftOx has a close cooperation with University of Copenhagen, University of Oslo and Malmö University. Professor Bjarnsholt from University of Copenhagen is also a member of SoftOx advisory board

Key financial partners

A Strong and Experienced Management and Financial Team Hans Petter Grette – Director Marketing • 20+ years' top management experience Geir H. Almås – Chief Executive Officer • Extensive experience from business • Previously PwC and KLP Asset Management • MSc in Business Administration (BI) and Dag Abrahamsen – Director Communication • 20+ years' experience working with Pharma-, Bio Tech- and health sector-related companies and • Specialist in Market Access, Reimbursement and • Law studies at the University of Bergen, as well

& Founder

- development in Norway and Poland

• Chartered Accountant (NHH)

• organizations
• Business Development within this industry

• as International Business Management and International Business Strategy at the Norwegian Business School

• Kristine Mundal Rød Finance Manager • 14+ years of experience in financial and nonfinancial reporting, auditing, forecasting, and strategy • Previously EY and Fretex Miljø/Salvation • State Authorized Public Accountant and

• Army
• Master of Business Administration in Economics (NHH)

Sales Norway

• working with market-leading branded consumer goods companies and within professional B2B industry • MSc Business Administration (BI), AGSIM
• (American Graduate School of International

• Management Thunderbird), Arizona, USA Finn Ketler – Director Marketing Sales EU • 20+ years' experience in Medtech, former SVP at Coloplast (DK, DE), CEO at Vigmed AB (SE), VP at Biotech Pharmacon (NO) and Selection Committee Member at BII a Novo Nordisk Foundation initiative • Managing Partner and Founder of Coopmed
  • where mission is to ensure more MedTech innovations reach market and help patients by supporting startups commercializing innovations

Affairs Manager

• Elisabeth A. Ohlsen QA & Regulatory • Several years of experience working with pharmaceutical companies and the health care sector • Expertise of how to operate a Quality • Civil Engineer in Pharmaceutical Design and
• Management System, Good Manufacturing Practice, and regulatory standards
• Engineering from the Technical University of Denmark

A Strong and Experienced Research and Development Management Team Glenn Gundersen – Director of Medical Affairs • Over 25 years of experience from the • Previously Bristol-Myers Squibb Norway, Biotec Pharmacon, Biogen Norway • PhD in Molecular and Cellular Biology, Magnus M. Fazli – Director of Science & • 15 years of experience in biofilm research • Specializing in chronic wound biofilms, biofilm • PhD in Medical Microbiology, University of Geir Utigard – Director of CMC • 20 years of experience in product and • Previously Lilleborg AS, Orkla, Axis-Shield AS • MSc in Chemical Engineering, NTNU Klaus Kirketerp-Møller – Principal Investigator • Since 2007, mainly focused on research on • Co-inventor of the technology with financial rights • Works for the company as a consultant • Medical Doctor, PhD at Copenhagen Wound Healing Center, Bispebjerg Hospital, Denmark Aina Kristin Pham – Industrial Ph.D Candidate • The company's formulation scientist and • Experience from the pharmaceutical field,

Management and research team Scientific advisory board

- - pharmaceutical industry with focus on immunology/inflammation and oncology

• University of Oslo

Research

• formation, and antibiotic resistance
• Copenhagen; MSc in Bio-Business and Innovation, Copenhagen Business School

• and health sector related companies
• Technical University of Berlin; PhD in Molecular Biology from the University of Oslo

Julia Robertson – Medical Research Manager • More than 8 years of experience in Pharma-• MSc in Medical Biotechnology from the

industrial PhD researcher

Oslo

• Master of Pharmacy from the University of Hanne Grøgaard – Scientist, CMC • Several years of experience in research, marketing documentation, analytical chemistry, product and process • Worked in start-ups and contributed to build and production processes. • MSc in Biotechnology, NTNU
• laboratories, systems, routines, methods

- - chronic wounds and bacterial biofilms

-

- Thomas Bjarnsholt Scientific Advisor • Expert in the role of bacterial and fungal biofilms in chronic infections with over 135 peer reviewed publications • Co-inventor of the technology with financial rights • Member of the Global Wound Biofilm Expert Panel • Professor at the Costerton Biofilm Center,

• Department of Immunology and Microbiology, University of Copenhagen Gruppen AS

• Pål Rongved Professor at the University of Oslo • Professor at School of Pharmacy, UiO and Senior Consultant in Board of Appeal Industrial Intellectual Property Rights (KFIR) • Specialties: Medicinal chemistry, contrast agents, • Cand.scient. in organic chemistry and PhD in

• chelating agents, innovation, IPR, patent technology.
• medicinal chemistry, UiO

• Attorney Thomas Meyers, Head of Intellectual Property, Brown Rudnick LLP » Main architect behind IP strategy and has worked with SoftOx since 2012 » Senior Advisor on chemical formulation and IP protection • SoftOx hand disinfectant (Allowed U.S. App. 15/167,076, and corresponding applications across the world) • SoftOx as a treatment for biofilms and wound care (U.S. App.15/612,571) Strong Intellectual Property rights

Advisors regarding patent and IP rights

• -
• Pål Rongved, Professor of Pharmaceutical Chemistry and Advisor for The Norwegian Industrial Property Office
  -

More than 20 fillings where key patents granted, some key applications regarding matter of use:

-

-

• SoftOx treatment of biofilms without inducing antimicrobial resistance (U.S. App. 16/672,393 and PCT/IB2019/001231); • SoftOx treatment of transient biofilms (U.S. App. 16/672,395 and PCT/IB2019/001177); and mastitis treatment (U.S. App. 14/618,820). • SoftOx has a license with co-inventors at the University of Copenhagen to patents related to wound treatment using SoftOx technology: Wound Care Products: U.S. 9,655,840 and EP 2515869; and Improved Wound Care Products: U.S. App. No. 14/112,518 and EP Pat. No. 2699232. Key patents filed in US, Europe, Asia and several South American countries

Ongoing patent application process to secure new inventions

Contents

- New Ways of Eradicating Infections

• The Product Portfolio
• Hand Disinfectant
• Wound Care Products
• • Respiratory Tract Solutions
  • Summary

SoftOx Product Development Methodology*

How to enter the market

21 * There are minor differences in the development stages between the products, for details, see each product description later in the presentation

Leading Players Emphasise Need for an Alternative to Alcohol

The World Health Organization recommendation to healthcare facilities [1

• «Provide alternative hand hygiene products for HCWs with confirmed allergies or adverse reactions to standard products used in the health-care setting» The Norwegian Hospitals (Helseforetakenes Innkjøpsservice AS (HINAS)) • Established a separate class for alcohol-free hand disinfectant

EXCITE International

• The expert panel which includes some of the largest customers in the US and UK (Kaiser Permanente, Mayo Clinic, NICE) acknowledges a great need for more skin friendly solutions and recommends SoftOx as a strategy for replacing Alcohol-Based Hand Rub SoftOx is answering an unmet need in a \$6 bn market in US and EU[2

• 1) World Health Organization Guidelines on Hand Hygiene in Health Care
• 2) Company own estimates

• Skin friendly alternative to 25-55% of healthcare workers (HCW) • Alternative to for 70% of HCW experience problems with alcohol • Full effect on all viruses incl. 15sec effect on enveloped viruses • Effective towards biofilm (hand eczema) SoftOx – a Paradigm Shift in Disinfection

Challenges answered by SoftOx

- have skin problems on their hands [1 • No health concerns » No burning sensation » Not toxic for eyes and drinking » Non-flammable

-

• -
  -
  -

Economic impact

31.5 million HCWs in the EU and the US [2 [3 Whereof 10 million have irritated skin and eczema[4

USD 1,080 [5 Value of effective prevention of hand eczema per HCW

1 mill HCWs in EU and US at risk of losing their job If so, 2/3 of them risk ending up on disability benefits

\$ 20 bn in estimated cost for US and European Hospitals

• 1) World Health Organization Guidelines on Hand Hygiene in Health Care
• 2) Eurostat- Majority of Health Jobs Held by Women (2020)
• 3) Kaiser Family Foundation Total Health Care Employment (2018)
• 4) National Eczema Association Hand Eczema Common Among Health Care Workers
• 5) MedValue+, Radbound University Medical Center and Exite International's Panel of 11 KOL/experts "2019 Health Technology Assessment; SoftOx Hand-wash for Health Care Workers with Eczema"

Relevance of Alcohol-Free Disinfection Products

Main Benefits

Safe usage in critical areas

Hand Disinfectant - Market Roll Out

Norway serves as a pilot market to better understand the post-Covid-19 consumer

SoftOx Disinfection Norway

Hospitals	Pharmacies & B2C	Other B2B
		Segment distributors • Cover the whole market • Signal customers
Rationale • Category for non-alcohol hand sanitizer • Well documented efficiency • Clinically proven skin friendly • Safe	Rationale • Norway's largest brand distributor • Own marketing, KAM and sales force towards pharmaceuticals • Category for "Infection prevention"	Doctors office Home Care Public & Private sector
Business model • HINAS Tender expected Des20/Jan21 • Direct of via distribution partners	partnering with Aeris facemasks • Innovation Window Feb 1st • Consumer activities: • XXL launched in NO/SV/DK • Now being used in EM Denmark • Product of the month jan 21 Br. Dahls	The defense sector International transport Sports Offshore
26

• Production facilities established in Norway » Three facilities for small bottles (up to 1 litre) » One facility for large bottles (1 litre and 5 litre) • Established QA system • Existing capacity up to 2,5 million liters per month » Focus on bottling and flexibility in bottle size and shape » New inhouse production line gives increased flexibility Production and Distribution – Hand Disinfection Production Distribution and roll out strategy

• -
  -
• -
  -

-

• Sales through distribution partners • Premium product, aimed at healthcare workers • Planned to be made available in pharmacies, sold directly to large clients and through consumer channels

Highly efficient production capacity for a turnover of up to \$ 70 million per year

Contents

Same Technology - Tailored Concentrations for Different Use

SoftOx Product Development Wound Irrigation Solutions (SWIS)

Market segmentation

• Safe to use (user friendly) • Non-toxic to host cells/tissue SoftOx Wound Irrigation Solution (SWIS)

Features

-

• Profound antimicrobial effect new resistance » Saline - 80% market share

Market opportunity

• risk profile and profound antimicrobial effect
  -
  -

-

• 31

SoftOx Product Development Infection Remover (SBE)

SoftOx Infection Remover (SBE)

Features

• Penetrates and kill microbes within biofilms
• Penetrates deep into the wound bed
• Non-toxic and safe to use
• Kills antibiotic resistant bacteria and does not induce new resistance

Development and market opportunity

• 40 million chronic wounds to heal [2
  -
• » Before healing, infections must be removed and includes surgical removal of wound bed

External market support

• EXCITE International incl. Blue Cross/Blue Shield
• European Wound Management Association

• 33

Contents

SoftOx Product Development Inhalation Solution

• Combat viral and bacterial infections in respiratory tract and lungs • Treatment of Covid-19 • Pneumonia, Cystic Fibrosis, other • Antiviral and antibacterial effects demonstrated in vitro • Tolerable & safe concentration range established in minipig model Treatment of Infections in the Respiratory Tract

Unmet need

-

-

Latest news

• A Scientific Advice meeting has been performed with Danish Medicines Agency obtaining clarity and input to an accelerated drug development process aiming for first-in-human (FIH) study Q2 2021. • Intensive research activity is currently ongoing to secure safety & tolerability aspects prior
• to FIH study. On schedule.

Answering the unmet medical need of treating respiratory tract infections

• Antimicrobial inhalation solution for respiratory tract infections • Broad spectrum including virus and resistance bacteria • Huge unmet need for infectious treatment in respiratory tract • Supplement for vaccine development • Replacing antibiotics to treat resistant infections SoftOx Inhalation Solution (SIS)

Features

-

Market opportunity

-

Project leader Professor Thomas Bjarnsholt

37 ¹ European Lung White-book, European Respiratory Society. Chapter 18. Available from: https://www.erswhitebook.org/chapters/acute-lower-respiratory-infections/ Number of cases from 31 Dec 2019 to 10 Aug 2020. Source: European Centre for Disease Control and Prevention. Available from: https://www.ecdc.europa.eu/en/geographical-distribution-2019-ncov-cases Disease burden of influenza. Source: Centers for Disease Control and Prevention. Available from: https://www.cdc.gov/flu/about/burden/index.html

Contents

New ways of eradicating infections and fighting antimicrobial resistance